ArticleFrontiers in cardiovascular medicine2022
Natural history and mid-term prognosis of severe tricuspid regurgitation: A cohort study.
Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Totally thoracoscopic beating-heart tricuspid valve repair 30 years after Ebstein's anomaly surgery: a case report and literature review.Journal of cardiothoracic surgery · 2026Review
- Contemporary insights and evolving clinical pathways in transcatheter tricuspid valve replacement.Herz · 2026Review
- Prognostic Modeling of Tricuspid Valve Regurgitation Outcomes Using Machine Learning-Based Survival Analysis.Journal of clinical medicine · 2026Article
- Why we need treatment? Prognosis of tricuspid regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Tricuspid valve edge to edge repair vs replacement - a comparative analysis and future directions.Future cardiology · 2026Review
- Transcatheter tricuspid valve intervention versus optimal medical therapy alone for severe tricuspid regurgitation: an updated meta-analysis with reconstructed time-to-event data.International journal of cardiology. Heart & vasculature · 2025Article
- SPEED-TR: a self-distilled and pre-trained transformer model for enhanced ECG detection of tricuspid regurgitation.NPJ digital medicine · 2025Article
- Choosing Between Tricuspid Repair or Replacement: Decision Algorithms.Structural heart : the journal of the Heart Team · 2025Review
- CT assessment of right heart anatomy across tricuspid regurgitation severity grades: implications for transcatheter interventions.The international journal of cardiovascular imaging · 2025Article
- Transcatheter Structural Heart Interventions in Women.Current cardiology reports · 2025Review
- Percutaneous interventions in tricuspid valve disease: a new era in cardiac treatment.Annals of medicine and surgery (2012) · 2025Review
- Late referrals and high mortality in tricuspid regurgitation: a call for timely intervention.European heart journal open · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The objective of this study was to characterize a population of patients with severe tricuspid regurgitation (TR) evaluated at a tertiary care center, assess mid-term clinical outcomes, and identify prognostic factors. Background: The impact of TR on morbidity and mortality is increasingly recognized. Clinical characteristics and long-term outcomes of patients suffering from TR remain unclear. Methods: This is a retrospective observational single-center study from a tertiary care hospital including patients with echocardiographic diagnosis of severe TR between January 2017 and December 2018. We used the Kaplan-Meier method to estimate survival for up to 4 years. After excluding patients with tricuspid valve (TV) intervention and surgery during follow-up, a multivariate analysis was performed to assess predictors of 2-year mortality using the Cox regression model. Results: A total of 278 patients (mean age 74.9 ± 13.7 years, 47.8% female) with severe TR were included in the study. The majority (83.1%; Conclusion: Our study shows the high burden of morbidity and the dismal survival of patients with severe TR. It also highlights the extent of the therapeutic need, since the vast majority of patients were left untreated. Additionally, CIED RV lead-associated TR was prevalent suggesting a need for more attention in clinical routine and research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.